Soft Tissue Sarcoma Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Others), By End User (Hospitals, Homecare, Specialty Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.71 Billion
CAGR (2026-2031)	8.44%
Fastest Growing Segment	Anti-angiogenesis Drugs
Largest Market	North America
Market Size (2031)	USD 2.78 Billion

Market Overview

The Global Soft Tissue Sarcoma Market will grow from USD 1.71 Billion in 2025 to USD 2.78 Billion by 2031 at a 8.44% CAGR. Soft tissue sarcoma constitutes a heterogeneous group of rare malignancies arising in connective tissues such as fat, muscle, blood vessels, and nerves. The global market for treating these conditions is primarily driven by the rising incidence of the disease and the accelerated development of novel therapeutic modalities, including targeted drugs and immunotherapies, which offer improved patient outcomes compared to traditional chemotherapy. According to the American Cancer Society, in 2025, approximately 13,520 new soft tissue sarcomas were projected to be diagnosed in the United States.

However, the market encounters a significant impediment in the form of high treatment costs associated with these advanced biologic therapies. This financial burden, coupled with stringent reimbursement policies in various regions, limits patient access to life-saving medications and restricts revenue generation for manufacturers. Consequently, affordability remains a critical challenge that could substantially hinder the broader expansion and adoption of effective treatments within the global soft tissue sarcoma market.

Key Market Drivers

Rapid advancements in targeted therapies and immunologics are fundamentally reshaping the global soft tissue sarcoma market, moving treatment paradigms beyond traditional chemotherapy. A pivotal development occurred with the FDA's accelerated approval of Tecelra (afamitresgene autoleucel) for synovial sarcoma, marking the first engineered cell therapy for a solid tumor. This innovation addresses significant unmet needs in patients with specific genetic markers, offering new hope where conventional options have failed. According to Adaptimmune Therapeutics, August 2024, in the 'SPEARHEAD-1' trial results, this therapy demonstrated an overall response rate of 43.2% among heavily pre-treated patients, significantly outperforming historical standards. The commercial viability of such breakthroughs underscores the market's potential; Adaptimmune Therapeutics further projected in August 2024 that its sarcoma franchise could generate approximately $400 million in peak yearly sales in the United States, highlighting the lucrative opportunities within this niche oncology segment.

Simultaneously, the increasing global incidence and prevalence of soft tissue sarcomas serve as a primary catalyst for market expansion. As populations age and diagnostic capabilities improve, the identified burden of these rare malignancies continues to rise, necessitating broader access to effective treatments and fueling demand for novel therapeutics. According to the Global Burden of Disease Study 2021, published in The Lancet in May 2024, the global annual incidence of soft tissue and extraosseous sarcomas reached 96,201 cases in 2021, reflecting a steady accumulation of disease burden over the last three decades. This growing patient pool compels pharmaceutical developers to accelerate their clinical pipelines and encourages healthcare systems to allocate greater resources toward specialized sarcoma care, thereby sustaining long-term market growth.

Download Free Sample Report

Key Market Challenges

The substantial financial burden associated with advanced therapeutic interventions constitutes a primary restraint on the growth of the global soft tissue sarcoma market. High acquisition costs for biologic agents and targeted therapies frequently exceed the coverage limits set by public and private payers. This pricing structure often results in stringent reimbursement protocols or coverage denials, effectively preventing a significant portion of the patient population from accessing necessary care. According to the National Cancer Institute, in 2024, the 5-year relative survival rate for soft tissue sarcoma was reported to be 65.8 percent.

This survival metric highlights the urgent need for consistent access to effective therapies, yet economic barriers significantly disrupt this access. When financial toxicity forces patients to forego treatment or settle for less effective alternatives, the market penetration of premium therapies is severely curtailed. Consequently, the disparity between clinical availability and patient affordability restricts the return on investment for manufacturers, thereby limiting the overall revenue potential and commercial expansion of the global market.

Key Market Trends

The integration of Artificial Intelligence (AI) in sarcoma diagnostics is emerging as a transformative trend, addressing the critical challenge of histological heterogeneity that often complicates accurate diagnosis. Advanced algorithms are now being utilized to analyze radiomic data from CT scans, enabling more precise tumor grading and subtype classification without the immediate need for invasive procedures. This technological leap facilitates earlier and more accurate interventions, directly influencing patient management strategies by reducing misdiagnosis rates. According to RAD Magazine, January 2024, in the 'Research shows AI helps tailor treatment for rare sarcomas more accurately than biopsy' article, a newly developed AI algorithm accurately predicted the disease type of 84% of the sarcomas tested, significantly outperforming the diagnostic accuracy of standard biopsy methods in differentiating between complex subtypes.

Simultaneously, the market is witnessing a strategic shift toward the adoption of liquid biopsy and circulating tumor DNA (ctDNA) analysis to overcome the limitations of traditional tissue sampling in monitoring disease progression. This non-invasive modality allows for the real-time detection of molecular residual disease and the identification of actionable genomic alterations, which is particularly vital for subtypes that lack recurrent driver mutations. According to the American Society of Clinical Oncology, May 2024, in the 'A multi-assay liquid biopsy approach to improve detection of bone and soft tissue sarcomas' abstract, circulating tumor material was successfully detected in 100% of fusion-negative rhabdomyosarcoma samples at the time of diagnosis, underscoring the high sensitivity of this approach for tracking hard-to-detect malignancies.

Segmental Insights

The Anti-angiogenesis Drugs segment is currently recognized as the fastest-growing category within the Global Soft Tissue Sarcoma Market due to the increasing shift toward targeted therapeutics over conventional chemotherapy. This rapid expansion is primarily driven by the demonstrated clinical efficacy of agents that inhibit tumor blood vessel formation, thereby restricting disease progression in advanced cases. Furthermore, favorable approval pathways from regulatory authorities such as the U.S. Food and Drug Administration for specific tyrosine kinase inhibitors have significantly accelerated commercial adoption. Consequently, healthcare providers are increasingly prioritizing these targeted interventions to manage late-stage soft tissue sarcomas effectively.

Regional Insights

North America maintains a leading position in the global soft tissue sarcoma market due to the high prevalence of the condition and substantial healthcare expenditure. The region benefits from extensive research and development initiatives driven by major pharmaceutical companies. Additionally, favorable regulatory frameworks provided by the United States Food and Drug Administration facilitate faster market entry for new therapies through mechanisms such as orphan drug designations. This regulatory support, combined with established reimbursement structures, ensures the sustained adoption of therapeutic treatments across the region.

Recent Developments

• In November 2024, Immutep Limited unveiled positive new data from the EFTISARC-NEO Phase II trial at the Connective Tissue Oncology Society Annual Meeting. The study evaluated the company's lead candidate, eftilagimod alpha, in combination with radiotherapy and pembrolizumab for patients with soft tissue sarcoma in a neoadjuvant setting. The results demonstrated a high pathological response rate and significant tumor hyalinization, surpassing historical outcomes for standard radiotherapy alone. These findings supported the potential of this triple-combination immunotherapy to enhance clinical efficacy for patients with resectable soft tissue sarcoma, contributing valuable research to the global soft tissue sarcoma market.
• In September 2024, Jazz Pharmaceuticals, in conjunction with its research partners, presented new clinical data concerning soft tissue sarcoma at the European Society for Medical Oncology Congress in Barcelona. The presentation detailed the safety and efficacy of lurbinectedin combined with ipilimumab and nivolumab for the treatment of advanced soft tissue sarcoma. The data provided insights into the potential synergistic effects of combining lurbinectedin with dual checkpoint inhibition, highlighting the company's ongoing commitment to expanding its oncology pipeline. By exploring such novel combination therapies, the company aimed to improve therapeutic outcomes for patients dealing with difficult-to-treat solid tumors in the global soft tissue sarcoma market.
• In August 2024, Adaptimmune Therapeutics received accelerated approval from the U.S. Food and Drug Administration for Tecelra (afamitresgene autoleucel), marking the first engineered cell therapy approved for a solid tumor in the United States. This treatment was authorized for adult patients with unresectable or metastatic synovial sarcoma who had previously received chemotherapy and whose tumors expressed the MAGE-A4 antigen. The approval was based on positive data from the SPEARHEAD-1 clinical trial, which showed a substantial overall response rate, representing a major product launch and therapeutic advancement within the global soft tissue sarcoma market.
• In June 2024, a significant clinical breakthrough involving Merck's immunotherapy drug, pembrolizumab, was announced at the American Society of Clinical Oncology Annual Meeting. A clinical trial supported by the company's Investigator Studies Program and sponsored by the Sarcoma Alliance for Research through Collaboration demonstrated that adding pembrolizumab to standard radiation and surgery reduced the risk of relapse by 43% in patients with high-risk soft tissue sarcoma of the extremity. The findings from this randomized Phase 2 study addressed a critical unmet need in the management of stage III soft tissue sarcoma, offering strong evidence that immunotherapy can significantly improve disease-free survival in the global soft tissue sarcoma market.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Viatris Inc
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer Inc.
• GSK plc
• Novartis AG
• Bayer AG
• Sun Pharmaceutical Industries Ltd.
• Merck & Co., Inc.

By Treatment Type	By End User	By Region
Targeted Therapy Chemotherapy Anti-Angiogenesis Drugs Radiation Therapy Others	Hospitals Homecare Specialty Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Soft Tissue Sarcoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Soft Tissue Sarcoma Market, By Treatment Type:

• Targeted Therapy
• Chemotherapy
• Anti-Angiogenesis Drugs
• Radiation Therapy
• Others

• Soft Tissue Sarcoma Market, By End User:

• Hospitals
• Homecare
• Specialty Centers
• Others

• Soft Tissue Sarcoma Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE